A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration

MLA

Stephen H. Poor, et al. “A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration.” American Journal of Ophthalmology, vol. 239, July 2022, pp. 180–89. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a19367ce37551cd725bf81ee513cc549&authtype=sso&custid=ns315887.

APA

Stephen H. Poor, Georges Weissgerber, Christopher M. Adams, Harit Bhatt, David J. Browning, James Chastain, Thomas A. Ciulla, Michael Ferriere, Kinfemichael Gedif, Louis C. Glazer, Brian C. Joondeph, Guillaume Normand, Veeral Sheth, Christie Watters, & Cynthia L. Grosskreutz. (2022). A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 239, 180–189.

Chicago

Stephen H. Poor, Georges Weissgerber, Christopher M. Adams, Harit Bhatt, David J. Browning, James Chastain, Thomas A. Ciulla, et al. 2022. “A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration.” American Journal of Ophthalmology 239 (July): 180–89. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a19367ce37551cd725bf81ee513cc549&authtype=sso&custid=ns315887.